149 related articles for article (PubMed ID: 35061546)
1. The nuclear-localized GHR is involved in the cell proliferation of gastric cancer, and pegvisomant may be an important potential drug to inhibit the proliferation of gastric cancer cells.
Meng Y; Zhou B; Pei Z; Chen Y; Chang D
Biochem Cell Biol; 2022 Apr; 100(2):125-135. PubMed ID: 35061546
[TBL] [Abstract][Full Text] [Related]
2. Endocytosis and Degradation of Pegvisomant and a Potential New Mechanism That Inhibits the Nuclear Translocation of GHR.
Lan H; Li W; Li R; Zheng X; Luo G
J Clin Endocrinol Metab; 2019 Jun; 104(6):1887-1899. PubMed ID: 30602026
[TBL] [Abstract][Full Text] [Related]
3. GH Action in Prostate Cancer Cells Promotes Proliferation, Limits Apoptosis, and Regulates Cancer-related Gene Expression.
Unterberger CJ; Maklakova VI; Lazar M; Arneson PD; Mcilwain SJ; Tsourkas PK; Hu R; Kopchick JJ; Swanson SM; Marker PC
Endocrinology; 2022 May; 163(5):. PubMed ID: 35383352
[TBL] [Abstract][Full Text] [Related]
4. Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance.
Muller AF; Janssen JA; Hofland LJ; Lamberts SW; Bidlingmaier M; Strasburger CJ; van der Lely AJ
J Clin Endocrinol Metab; 2001 Feb; 86(2):590-3. PubMed ID: 11158013
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation.
Lincoln DT; Singal PK; Al-Banaw A
Anticancer Res; 2007; 27(6B):4201-18. PubMed ID: 18225592
[TBL] [Abstract][Full Text] [Related]
6. Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly.
Parkinson C; Trainer PJ
Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S119-23. PubMed ID: 10984267
[TBL] [Abstract][Full Text] [Related]
7. In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.
Cuny T; Zeiller C; Bidlingmaier M; Défilles C; Roche C; Blanchard MP; Theodoropoulou M; Graillon T; Pertuit M; Figarella-Branger D; Enjalbert A; Brue T; Barlier A
Endocr Relat Cancer; 2016 Jul; 23(7):509-19. PubMed ID: 27267119
[TBL] [Abstract][Full Text] [Related]
8. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth.
Divisova J; Kuiatse I; Lazard Z; Weiss H; Vreeland F; Hadsell DL; Schiff R; Osborne CK; Lee AV
Breast Cancer Res Treat; 2006 Aug; 98(3):315-27. PubMed ID: 16541323
[TBL] [Abstract][Full Text] [Related]
9. 22-kD growth hormone-induced nuclear GHR/STAT5/CyclinD1 signaling pathway plays an important role in promoting mesenchymal stem cell proliferation.
Zheng WV; Li Y; Xu Y; Zhou T; Li D; Cheng X; Xiong Y; Wang S; Chen Z
Biofactors; 2022 Jan; 48(1):67-85. PubMed ID: 34866251
[TBL] [Abstract][Full Text] [Related]
10. Effect of different growth hormone (GH) mutants on the regulation of GH-receptor gene transcription in a human hepatoma cell line.
Deladoëy J; Gex G; Vuissoz JM; Strasburger CJ; Wajnrajch MP; Mullis PE
Eur J Endocrinol; 2002 Apr; 146(4):573-81. PubMed ID: 11916628
[TBL] [Abstract][Full Text] [Related]
11. Lessons learned from studies with the growth hormone receptor.
Kopchick JJ
Growth Horm IGF Res; 2016 Jun; 28():21-5. PubMed ID: 26216709
[TBL] [Abstract][Full Text] [Related]
12. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.
Bernabeu I; Alvarez-Escolá C; Quinteiro C; Lucas T; Puig-Domingo M; Luque-Ramírez M; de Miguel-Novoa P; Fernandez-Rodriguez E; Halperin I; Loidi L; Casanueva FF; Marazuela M
J Clin Endocrinol Metab; 2010 Jan; 95(1):222-9. PubMed ID: 19850678
[TBL] [Abstract][Full Text] [Related]
13. Regulation of growth-hormone-receptor gene expression by growth hormone and pegvisomant in human mesangial cells.
Meinhardt U; Eblé A; Besson A; Strasburger CJ; Sraer JD; Mullis PE
Kidney Int; 2003 Aug; 64(2):421-30. PubMed ID: 12846737
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model.
Evans A; Jamieson SM; Liu DX; Wilson WR; Perry JK
Cancer Lett; 2016 Aug; 379(1):117-23. PubMed ID: 27241667
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications.
Kopchick JJ; List EO; Kelder B; Gosney ES; Berryman DE
Mol Cell Endocrinol; 2014 Apr; 386(1-2):34-45. PubMed ID: 24035867
[TBL] [Abstract][Full Text] [Related]
16. Conditional gene regulation models demonstrate a pro-proliferative role for growth hormone receptor in prostate cancer.
Unterberger CJ; McIlwain SJ; Tsourkas PK; Maklakova VI; Prince JL; Onesti A; Hu R; Kopchick JJ; Swanson SM; Marker PC
Prostate; 2023 Apr; 83(5):416-429. PubMed ID: 36562110
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone receptor in dopaminergic neurones regulates stress-induced prolactin release in male mice.
Wasinski F; Chaves FM; Pedroso JAB; Mansano NS; Camporez JP; Gusmão DO; List EO; Kopchick JJ; Frazão R; Szawka RE; Donato J
J Neuroendocrinol; 2021 Mar; 33(3):e12957. PubMed ID: 33769619
[TBL] [Abstract][Full Text] [Related]
18. Regulation of growth hormone receptors in human prostate cancer cell lines.
Bidosee M; Karry R; Weiss-Messer E; Barkey RJ
Mol Cell Endocrinol; 2009 Oct; 309(1-2):82-92. PubMed ID: 19540305
[TBL] [Abstract][Full Text] [Related]
19. MECHANISMS IN ENDOCRINOLOGY: Clinical and pharmacogenetic aspects of the growth hormone receptor polymorphism.
Boguszewski CL; Barbosa EJL; Svensson PA; Johannsson G; Glad CAM
Eur J Endocrinol; 2017 Dec; 177(6):R309-R321. PubMed ID: 28904008
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.
Kopchick JJ; Parkinson C; Stevens EC; Trainer PJ
Endocr Rev; 2002 Oct; 23(5):623-46. PubMed ID: 12372843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
